Ibudilast for Treating Alcohol Use Disorder

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 14, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Alcohol Use Disorder (AUD)Alcoholism
Interventions
DRUG

Ibudilast

IBUD at a dosage of 20 mg twice daily for 2 days, with an increase to 50 mg twice daily on day 3. The dosage will remain at 50 mg twice daily through most of the rest of the 6-week treatment period. However, for the last three days of week 6, participants will reduce the dosage gradually to 20 mg twice daily prior to discontinuing it at the end of the treatment period.

BEHAVIORAL

Medical management

All subjects receive 6 weeks of medical management (Pettinati et al. 2004) will support subjects efforts to reduce or stop their drinking.

DRUG

Placebo

Placebo twice daily for 6-week treatment period. Placebo will match active medication in appearance and size.

Trial Locations (1)

19104

University of Pennsylvania Center for Studies of Addiction, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER